Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
May 17 2022 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology
company focused on the development of next generation nucleic acid
therapies targeting RNA to address both genetic and non-genetic
neurological disorders and hair loss disorders, today announced
that CEO Matthias Schroff will provide a virtual presentation at
the 2022 H.C. Wainwright Global Life Sciences Conference, occurring
May 23-26, 2022.
The presentation will be available for on-demand viewing
beginning May 24, 2022 at 7:00AM EST via the virtual conference
link, and will be archived for 90 days.
Exicure will be taking 1x1 investor meetings with registered
conference attendees.
About Exicure
Exicure, Inc. is an early-stage biotechnology company developing
nucleic acid therapies targeting ribonucleic acid against validated
targets to neurological disorders and hair loss. The team includes
a diverse scientific group with expertise in nucleic acid
chemistry, drug development and neuroscience. Headquartered in
Chicago, Illinois, the Company conducts its discovery and
development efforts in-house with a dedicated 30,000 square foot
facility, including rapid and automated high throughput nucleic
acid synthesis and screening. For further information, see
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517005381/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macdougall.bio
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Sep 2023 to Sep 2024